GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

Sight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total € 18.5 million funding for SIGHT AGAIN as part of the Investment for the Future

GenSight Biologics announced today the closing of a €32 million Series A financing for Ophthalmic Gene Therapy.